Sandra Weintraub1,2, Tatiana Karpouzian-Rogers1,2, John Devin Peipert3, Cindy Nowinski3,4, Jerry Slotkin5, Katy Wortman3, Emily Ho3, Emily Rogalski1,2, Cynthia Carlsson6, Bruno Giordani7, Felicia Goldstein8, John Lucas9, Jennifer J Manly10, Dorene Rentz11, David Salmon12, Beth Snitz13, Hiroko H Dodge14, Michaela Riley1, Fatima Eldes1, Vitali Ustsinovich3, Richard Gershon3. 1. Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. 2. Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. 3. Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. 4. Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. 5. Center for Health Assessment Research and Translation, University of Delaware, Newark, Delaware, USA. 6. Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health and Wisconsin Alzheimer's Disease Research Center, Madison, Wisconsin, USA. 7. Department of Psychiatry, University of Michigan, Ann Arbor, Michigan, USA. 8. Department of Neurology, Emory University, Atlanta, Georgia, USA. 9. Department of Psychiatry and Psychology, Mayo Clinic, Jacksonville, Florida, USA. 10. Department of Neurology, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, Columbia University, New York, New York, USA. 11. Department of Neurology, Massachusetts General Hospital and Brigham and Women's Hospital, Harvard Medical School, Boston, USA. 12. Department of Neurosciences, University of California San Diego, La Jolla, California, USA. 13. Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. 14. Department of Neurology, Layton Aging and Alzheimer's Disease Center, Oregon Health & Science University, Portland, Oregon, USA.
Abstract
INTRODUCTION: Early detection of cognitive decline in older adults is a public health priority. Advancing Reliable Measurement in Alzheimer's Disease and Cognitive Aging (ARMADA), a multisite study, is validating cognition, emotion, motor, and sensory modules of the National Institutes of Health Toolbox for Assessment of Neurological and Behavioral Function (NIHTB) in the aging spectrum from cognitively normal to dementia of the Alzheimer's type (DAT). METHODS: Participants 65 to 85 years old, in demographic groups racially proportional to the general US population, are recruited in one of three groups to validate the NIHTB: cognitively normal, amnestic mild cognitive impairment (aMCI), or mild DAT. Additional special emphasis cohorts include (1) Blacks in the three clinical groups; (2) Spanish-speakers in the three clinical groups; (3) cognitively normal, population-proportional, over age 85. DISCUSSION: Longitudinal study will determine whether NIHTB can predict cognitive decline and is associated with Alzheimer's disease biomarkers. Here, we detail the methods for the ARMADA study.
INTRODUCTION: Early detection of cognitive decline in older adults is a public health priority. Advancing Reliable Measurement in Alzheimer's Disease and Cognitive Aging (ARMADA), a multisite study, is validating cognition, emotion, motor, and sensory modules of the National Institutes of Health Toolbox for Assessment of Neurological and Behavioral Function (NIHTB) in the aging spectrum from cognitively normal to dementia of the Alzheimer's type (DAT). METHODS: Participants 65 to 85 years old, in demographic groups racially proportional to the general US population, are recruited in one of three groups to validate the NIHTB: cognitively normal, amnestic mild cognitive impairment (aMCI), or mild DAT. Additional special emphasis cohorts include (1) Blacks in the three clinical groups; (2) Spanish-speakers in the three clinical groups; (3) cognitively normal, population-proportional, over age 85. DISCUSSION: Longitudinal study will determine whether NIHTB can predict cognitive decline and is associated with Alzheimer's disease biomarkers. Here, we detail the methods for the ARMADA study.
Authors: Matthew R Woodward; Chaitanya V Amrutkar; Harshit C Shah; Ralph H B Benedict; Sanjanaa Rajakrishnan; Rachelle S Doody; Li Yan; Kinga Szigeti Journal: Neurol Clin Pract Date: 2017-02
Authors: D P Devanand; Seonjoo Lee; Jennifer Manly; Howard Andrews; Nicole Schupf; Richard L Doty; Yaakov Stern; Laura B Zahodne; Elan D Louis; Richard Mayeux Journal: Neurology Date: 2014-12-03 Impact factor: 9.910
Authors: Victor L Villemagne; Samantha Burnham; Pierrick Bourgeat; Belinda Brown; Kathryn A Ellis; Olivier Salvado; Cassandra Szoeke; S Lance Macaulay; Ralph Martins; Paul Maruff; David Ames; Christopher C Rowe; Colin L Masters Journal: Lancet Neurol Date: 2013-03-08 Impact factor: 44.182
Authors: Katherine L Possin; Victor R Laluz; Oscar Z Alcantar; Bruce L Miller; Joel H Kramer Journal: Neuropsychologia Date: 2010-10-26 Impact factor: 3.139
Authors: Rosebud O Roberts; Teresa J H Christianson; Walter K Kremers; Michelle M Mielke; Mary M Machulda; Maria Vassilaki; Rabe E Alhurani; Yonas E Geda; David S Knopman; Ronald C Petersen Journal: JAMA Neurol Date: 2016-01 Impact factor: 18.302